A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

• Status: RECRUITING
• Trial end date: 2027-08-31

Summary

To evaluate the efficacy of Surufatnib combined withcamrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer

• Phase: PHASE2

Details

• Lead Sponsor: Hutchmed
• Treatments: 130-nm albumin-bound paclitaxel; camrelizumab; Gemcitabine; surufatinib